Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CALCA | P06881 | 8/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775386 | 0.93 | CYP2C9 (0.37) | CYP2C9CALCAKCNH2KCNE1CCR1 | |
| SCHEMBL12775401 | 0.92 | CYP2C9 (0.38) | CYP2C9CALCAKCNH2KCNE1CCR1 | |
| SCHEMBL12775413 | 0.89 | CYP2C9 (0.35) | CYP2C9CALCAKCNH2KCNE1CCR1 | |
| SCHEMBL1118846 | 0.86 | CYP2C9 (0.36) | CYP2C9CALCAKCNH2KCNE1CCR1 | |
| SCHEMBL4822949 | 0.86 | CYP2C9 (0.37) | CYP2C9CALCAKCNH2KCNE1CCR1 | |
| SCHEMBL4830759 | 0.86 | CYP2C9 (0.37) | CYP2C9CALCAKCNH2KCNE1CCR1 | |
| SCHEMBL12775360 | 0.85 | CYP2C9 (0.38) | CYP2C9CALCAKCNH2 | |
| SCHEMBL12775452 | 0.85 | CYP2C9 (0.35) | CYP2C9CALCAKCNH2KCNE1CCR1 | |
| SCHEMBL4829057 | 0.85 | CYP2C9 (0.37) | CYP2C9CALCAKCNH2KCNE1CCR1 | |
| SCHEMBL2530290 | 0.85 | CYP2C9 (0.35) | CYP2C9CALCAKCNH2KCNE1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897592-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897592-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070112190-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070112190-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112190-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | CYP2C9 662/4885CALCA 2607/4885KCNH2 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.